Xin Lang Cai Jing·2025-09-08 02:36Core Viewpoint - Baiyunshan Pharmaceutical Group has shown mixed financial performance with slight revenue growth but a decline in net profit, alongside significant trading activity in its stock [2][3]. Financial Performance - For the first half of 2025, Baiyunshan achieved operating revenue of 41.835 billion yuan, representing a year-on-year increase of 1.93% [2]. - The net profit attributable to shareholders was 2.516 billion yuan, reflecting a year-on-year decrease of 1.31% [2]. Stock Trading Activity - On September 5, Baiyunshan's stock price increased by 0.34%, with a trading volume of 237 million yuan [1]. - The financing buy-in amount for Baiyunshan on the same day was 28.51 million yuan, while the financing repayment was 51.72 million yuan, resulting in a net financing outflow of 23.22 million yuan [1]. - As of September 5, the total financing and securities lending balance for Baiyunshan was 974 million yuan, with the financing balance accounting for 2.61% of the circulating market value [1]. Shareholder Information - As of June 30, 2025, Baiyunshan had 85,500 shareholders, a decrease of 8.54% from the previous period [2]. - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares [3].